Sertraline in social phobia.
Twenty-two patients meeting a primary DSM-III-R diagnosis of Social Phobia, entered a 12 week open trial of sertraline. Twenty patients completed at least 8 weeks of treatment. Sixteen patients (80%) were considered responders and 4 (20%) were considered non-responders. All measures of social anxiety and avoidance, depression and social functioning showed a statistically significant change from baseline to end point.
Van Ameringen
M
M
Department of Psychiatry, McMaster University, Hamilton, Ontario, Canada.
Mancini
C
C
Streiner
D
D
D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001008:Anxiety Disorders / Q000150:complications; D015897:Comorbidity; D003866:Depressive Disorder / Q000150:complications; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010624:Phenelzine / Q000009:adverse effects / Q000627:therapeutic use*; D010698:Phobic Disorders / Q000150:complications / Q000188:drug therapy*; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales; D019966:Substance-Related Disorders / Q000150:complications
D010624:Phenelzine